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Mouse modelCoenzyme Q10 (CoQ10) deﬁciency (MIM 607426) causes a mitochondrial syndrome with variability in the clin-
ical presentations. Patients with CoQ10 deﬁciency show inconsistent responses to oral ubiquinone-10 supple-
mentation, with the highest percentage of unsuccessful results in patients with neurological symptoms
(encephalopathy, cerebellar ataxia or multisystemic disease). Failure in the ubiquinone-10 treatment may be
the result of its poor absorption and bioavailability, which may be improved by using different pharmacological
formulations. In amousemodel (Coq9X/X) of mitochondrial encephalopathy due to CoQ deﬁciency, we have eval-
uated oral supplementation with water-soluble formulations of reduced (ubiquinol-10) and oxidized (ubiqui-
none-10) forms of CoQ10. Our results show that CoQ10 was increased in all tissues after supplementation with
ubiquinone-10 or ubiquinol-10, with the tissue levels of CoQ10 with ubiquinol-10 being higher than with
ubiquinone-10. Moreover, only ubiquinol-10was able to increase the levels of CoQ10 inmitochondria from cere-
brum of Coq9X/X mice. Consequently, ubiquinol-10 was more efﬁcient than ubiquinone-10 in increasing the ani-
mal body weight and CoQ-dependent respiratory chain complex activities, and reducing the vacuolization,
astrogliosis and oxidative damage in diencephalon, septum–striatum and, to a lesser extent, in brainstem.
These results suggest thatwater-soluble formulations of ubiquinol-10may improve the efﬁcacy of CoQ10 therapy
in primary and secondary CoQ10 deﬁciencies, other mitochondrial diseases and neurodegenerative diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Coenzyme Q10 (CoQ) is a lipophilic molecule that is involved in the
mitochondrial ATP synthesis because of its function as an electron be-
tweenmitochondrial complexes I and II, as well as ETF:Q oxidoreductase,
and mitochondrial complex III [1]. Moreover, CoQ10 functions as an anti-
oxidant,whichprotects the cells bothdirectly bypreventing the oxidation
of biomolecules and indirectly by regenerating other antioxidants such as
vitamins C and E [1]. Due to these properties, oral supplementation with
CoQ10 (in its stable oxidized form, ubiquinone-10) has been proposed
for the treatment of diseases involving mitochondrial dysfunction and/
or oxidative stress, i.e. primary mitochondrial disorders, Parkinson's Dis-
ease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Huntington'sE, Blue Native Poly-Acrylamide
e Q9; CoQ10, Coenzyme Q10;
voprotein; GFAP, Glial ﬁbrillary
rformance liquid chromatogra-
médica, lab 139, Universidad de
Granada, Spain. Tel.: +34 958Disease or heart failure [2–6]. Moreover, oral ubiquinone-10 sup-
plementation is the main choice in the treatment of primary
(MIM 607426) and secondary CoQ10 deﬁciencies [7].
Despite the good expectation that ubiquinone-10 therapy has
presented, the studies in different diseases, both at preclinical
and clinical levels, have shown contradictory results. Specially,
ubiquinone-10 seems to be less effective in improving the neuro-
logical symptoms and, in some cases, higher doses are needed to
appreciate some clinical improvement [7]. The mild or completely
lack of response to ubiquinone-10 therapy has been attributed to
its low absorption and bioavailability that limit the increase of
CoQ10 in cell mitochondria, where it is biologically active [8]. This
limitation is even more important in the brain because the exoge-
nous ubiquinone-10 must be able to cross the blood brain barrier.
Thus, different strategies have been investigated to increase the ab-
sorption and bioavailability of the exogenous CoQ10. In this regard,
water-soluble formulations of ubiquinone-10 seem to increase its
bioavailability. Different studies have shown that concentration
of CoQ10 in plasma after administration of water-soluble formula-
tions of ubiquinone-10 is higher than that after supplementation
with ubiquinone-10 administered as powder water-insoluble for-
mulations [8]. Moreover, the plasma levels of CoQ10 are also higher
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CoQ10, than when it is administered as ubiquinone-10 [8].
To evaluate whether water soluble formulations of ubiquinone-10,
as well as the use of the reduced form, ubiquinol-10, may increase the
efﬁcacy of CoQ10 therapy in the nervous system, in this study we have
used water-soluble formulations of ubiquinone-10 and ubiquinol-10
to treat a mouse model of mitochondrial encephalopathy and CoQ deﬁ-
ciency due to Coq9mutations (Coq9X/X) [9].2. Materials and methods
2.1. Mice use and experimental treatment
Generation and characterization of Coq9X/X mice (C57BL/6 genetic
background) were previously reported [9]. All experiments were per-
formed according to a protocol approved by the Institutional Animal
Care and Use Committee of the University of Granada (procedures
CEEA 2009-254 and 2010-275) and were in accordance with the
European Convention for the Protection of Vertebrate Animals used
for Experimental and Other Scientiﬁc Purposes (CETS # 123) and the
Spanish laws (32/2007 and R.D. 1201/2005). Mice were housed in the
Animal Facility of the University of Granada under a speciﬁc pathogen
free zonewith lights on at 7:00 AM and off at 7:00 PM, and with unlim-
ited access to water and rodent chow. Mice were sacriﬁced using CO2
narcosis followed by cervical dislocation at 3 months of age.
The treatment consisted of administering ubiquinone-10 or
ubiquinol-10 in the drinking water in a dose of 240 mg/kg bw/day. The
treatment started at 1 month of age and the mice were sacriﬁced at
3 months of age. Ubiquinone-10 and ubiquinol-10 were provided by
Kaneka Corporation (Japan) in a water-soluble formulation that contains
dextrin, Arabic gum and ascorbic acid. A control groupwith vehicle at the
same dose was also studied. The drinking water was changed twice a
week.2.2. Mitochondrial isolation
Cerebrumwas homogenized in a glass-Teﬂon homogenizer in a pro-
portion 1:5, w/v, in the homogenization medium A (0.32 M sucrose,
1 mM EDTA, 10 mM Tris–HCl [pH 7.4]) plus 0.2% fatty acid–free bovine
serumalbumin. Homogenatewas centrifuged at 1000 g for 5min at 4 °C
to remove nuclei and debris. Mitochondria were collected from super-
natants after centrifuging at 14,400 g for 2min at 4 °C. Themitochondri-
al pellet was suspended in the corresponding buffer and an aliquot of
each sample was used for protein determination [9].2.3. Quantiﬁcation of CoQ9 and CoQ10 levels in plasma, mice tissues and
cerebrum mitochondria
CoQ9 andCoQ10 frommice tissueswere extracted bymixing tissue ex-
tractswith 1-propanol. After 2min vortex, the solutionwas centrifuged at
11,300 g for 5 min. The resultant supernatant contained the lipid extract
[9]. CoQ9 and CoQ10 from plasma and cerebrum mitochondria were ex-
tracted in a hexane:ethanol mixture [10]. The lipid extract was injected
in a HPLC system (Gilson, WI, USA) and the lipid components were sepa-
rated by a reverse phase Symmetry C18 3.5 μm, 4.6 × 150 mm column
(Waters, Spain), using a mobile phase consisting of methanol, ethanol,
2-propanol, acetic acid (500:500:15:15) and 50 mM sodium acetate at a
ﬂow rate of 0.9 ml/min. The electrochemical detector consisted of an
ESA Coulochem III with the following setting: guard cell (upstream of
the injector) at +900 mV, conditioning cell at−600 mV (downstream
of the column), followed by the analytical cell at +350 mV [9]. CoQ9
and CoQ10 concentrations were estimated by comparison of the peak
areas with those of standard solutions of known concentrations. The re-
sults were expressed in ng CoQ/mg prot.2.4. CoQ-dependent respiratory chain activities
CoQ dependent respiratory chain activities were measured in submi-
tochondrial particles. To prepare submitochondrial particles, each mito-
chondrial pellet (100 μg prots) was suspended and sonicated in 100 μl
of 0.1 M potassium phosphate buffer, pH 7.5. Complex I + III activity
was measured at 30 °C in the presence of 0.5 mM potassium cyanide,
0.2 mM NADH and 0.1 mM cytochrome c, as the rotenone-sensitive re-
duction of cytochrome c at 550 nm [9,11]. The results were expressed in
nmol reduced cyt c/min/mg prot. Complex II + III activity was measured
at 30 °C in the presence of 0.5 mM KCN, 0.3 mM succinate and 0.01 mM
rotenone. The reaction was initiated by addition of 0.1 mM cytochrome
c and decrease in absorbance was monitored at 550 nm. The results
were expressed in nmol reduced cyt c/min/mg prot [11].
2.5. Blue native gel electrophoresis and immunoblotting for the evaluation
of mitochondrial supercomplex pattern
Bluenative gel electrophoresis (BNGE)wasperformed onmitochon-
drial fraction fromcerebrum. Themitochondrial pelletswere suspended
in 140 μl in the homogenization medium A. An aliquot of each sample
was used for protein determination. The remaining samples were then
centrifuged at 17,000 g for 3 min at 4 °C. Mitochondrial pellets were
suspended in an appropriate volume of buffer B (1 M 6-amiohexanoic
acid, 50 mM Bis-Tris–HCl [pH 7.0]) to be at 10 mg/ml, and the mem-
brane proteins were solubilized by the addition of digitonin (4 g/g)
and incubated for 5 min in ice. After 30 min centrifugation at 13,000 g,
the supernatant was collected, and 3 μl of 5% Brilliant Blue G dye pre-
pared in 1 M 6-amiohexanoic acid was added [9]. Mitochondrial pro-
teins (100 μg) were then applied and ran on a 3%–13% gradient native
gel using electrophoresis system mini-PROTEAN Tetra Cell (Bio-rad).
Western blot was performed using a mini Trans-blot Cell onto PVDF
membranes and probes with speciﬁc antibodies against complex I, anti-
NUDFA9 (Abcam, ab14713), complex III, anti-ubiquinol-cytochrome c re-
ductase Core Protein I (Abcam, ab110252) and Vdac1 (Abcam, ab14734)
[9,12].
2.6. Mitochondrial complex I in-gel catalytic activity assay
Mitochondrialmembrane proteins (100 μg)were applied and ran on
a 3%–13% ﬁrst-dimension gradient BNGE gel as described elsewhere
[13]. The assay buffer contained 10 mg of NTB and 0.14 mM NADH
added to 10ml of 100mMTris/HCl, pH 7.4. After about 30min the reac-
tion was stopped using 5 mM Tris/HCl, pH 7.4 and scanned for densito-
metric quantitation.
2.7. Histology and Immunohistochemistry
Mice tissues were formalin-ﬁxed and parafﬁn-embedded. Multiple
sections (4 μm thickness) were deparafﬁnized with xylene and stained
with hematoxylin and eosin (H&E). Immunohistochemistry was carried
out in the same sections, using the following primary antibodies: anti-
glial ﬁbrillary acidic protein (GFAP) (Millipore, MAB360), anti-Neuronal
Class III β-tubulin (TUJ1) (Covance, MMS-435P) and anti-8-hydroxy-2′-
deoxyguanosine (8-OHdG) (QED Bioscience, 12501). Dako Animal Re-
search Kit for mouse primary antibodies (Dako Diagnóstico S.A., Spain)
was used for the qualitative identiﬁcation of antigens by lightmicroscopy.
Sections were examined at 40–400 magniﬁcations with an OLYMPUS
CX41microscope, and the images were scanned under equal light condi-
tions with the CELL A computer program [9].
2.8. Statistical analysis
All statistical analyses were performed using the GraphPad scientiﬁc
software. Data are expressed as themean±SDof seven–ten experiments
per group. A one-way ANOVA with a Tukey post hoc test was used to
Table 1
Concentration of CoQ9 and CoQ10 in plasma of 3 months old mice after two months of
treatment.
Experimental group Plasma CoQ9 (μM) Plasma CoQ10 (μM)
Coq9+/+ 0.27 ± 0.03 UND
Coq9X/X + V 0.09 ± 0.01 ⁎⁎ UND
Coq9X/X + Q10 0.07 ± 0.01 ⁎⁎ 1.36 ± 0.67
Coq9X/X + Q10H2 0.05 ± 0.02 ⁎⁎ 2.06 ± 0.65
Data are expressed as mean ± SD of seven animals per group. V = vehicle; Q10 =
ubiquinone-10; Q10H2 = ubiquinol-10. UND = undetectable.
⁎⁎ P b 0.01 versus Coq9+/+.
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ered to be statistically signiﬁcant.
3. Results
3.1. CoQ10 levels in plasma and tissues of Coq9
X/X after 2 months
of treatment
We previously reported that Coq9X/X mice showed a signiﬁcant
decrease in both CoQ9 (the major form of ubiquinone in rodents)
and CoQ10 levels at 3 months of age compared with the age-mated
Coq9+/+ mice in all examined tissues (cerebrum, cerebellum, heart,
kidney, hind legs skeletal muscle and liver) [9]. Two months of
ubiquinone-10 or ubiquinol-10 therapies increased plasma levels of
CoQ10 in Coq9X/X mice, while levels of CoQ9 did not change in the
same animals (Table 1). Treatment with vehicle did not produce
any effects in the plasma CoQ10 levels. In tissues, a signiﬁcant in-
crease of CoQ10 after ubiquinone-10 treatment was only detected
in liver and muscle. On the contrary, CoQ10 levels were signiﬁcantly
increased in the cerebrum, cerebellum, heart, kidney, liver and
hind leg skeletal muscle of Coq9X/X mice treated with ubiquinol-10
(Fig. 1). The increase of CoQ10 levels after ubiquinone-10 or ubiquinol-Fig. 1. Ubiquinone-10 and ubiquinol-10 increase tissue levels of CoQ10 in Coq9X/Xmice. CoQ10 leve
10) and Coq9X/X+Q10H2 (N= 10) mice after 2 months of treatment. Data are expressed as mean
***P b 0.005 versus Coq9+/+; #P b 0.05, and ##P b 0.01 versus Coq9X/X + V; +P b 0.05 versus Co10 treatments was in parallel to a decrease in the CoQ9/CoQ10 ratio
(Fig. S1), which indicates that these therapies did not affect the CoQ9
levels (Fig. S2). Compared to the vehicle group, the highest increase of
CoQ10 after ubiquinone-10 or ubiquinol-10 treatments was found in
liver and muscle, followed by heart, kidney, cerebrum and cerebellum.
Onlymuscle and heart of Coq9X/Xmice treatedwith ubiquinol-10 reached
similar CoQ10 levels than that of Coq9+/+ mice, while liver accumulated
huge amounts of CoQ10 after ubiquinone-10 or ubiquinol-10 treatment
(Fig. 1).
3.2. CoQ levels in cerebral mitochondria of Coq9X/X after 2 months
of treatment
Because Coq9X/X mice develop mitochondrial encephalopathy [9], we
evaluated the effects of the therapies onmitochondrial CoQ levels andmi-
tochondrial respiratory chain function in cerebrum of the mutant mice.
Mitochondrial CoQ10 levels were signiﬁcantly increased only after
ubiquinol-10 treatment in Coq9X/X mice, while vehicle or ubiquinone-10
supplementation did not increase the mitochondrial CoQ10 levels
(Fig. 2A). Considering the total mitochondrial CoQ pool (CoQ9 + CoQ10),
ubiquinol-10 treatment increased mitochondrial CoQ levels (Fig. 2B)
and decreased the CoQ9/CoQ10 ratio after ubiquinol-10 treatment
(Fig. 2C).
3.3. CoQ-dependent mitochondrial respiratory chain activities and
supercomplex pattern in cerebral mitochondria of Coq9X/X after 2 months
of treatment
Cerebral mitochondria of Coq9X/X mice treated with vehicle showed
a signiﬁcant decrease of CI + III and CII + III activities compared to
those of Coq9+/+ mice (Fig. 2D and E). Similarly to the Pdss2kd/kd mice,
the decrease in CI + III activity was higher than the decrease in CII + III
activity [14]. The increase of CoQ10 levels in cerebral mitochondria ofls in tissue homogenates from Coq9+/+ (N=10), Coq9X/X+V (N=10), Coq9X/X+Q10 (N=
± SD. V= vehicle; Q10= ubiquinone-10; Q10H2= ubiquinol-10. *P b 0.05, **P b 0.01, and
q9X/X + Q10.
Fig. 2.Mitochondria from cerebrum of Coq9X/X mice show an increase of CoQ10 levels and CoQ-dependent respiratory chain activities after ubiquinol-10 treatment. (A) CoQ10 levels,
(B) CoQ9 + CoQ10 levels and (C) CoQ9/CoQ10 ratio in cerebrum mitochondria of Coq9+/+ (N = 7), Coq9X/X + V (N = 7), Coq9X/X + Q10 (N = 7) and Coq9X/X + Q10H2 (N = 7) mice
after 2 months of treatment. CoQ-dependent mitochondria respiratory chain activities represented by (D) CI + III and (E) CII + III. Data are expressed as mean ± SD. V = vehicle; Q10 =
ubiquinone-10; Q10H2 = ubiquinol-10. *P b 0.05, **P b 0.01, and ***P b 0.005 versus Coq9+/+; #P b 0.05; ##P b 0.01 versus Coq9X/X + V; +P b 0.05, ++P b 0.01 versus Coq9X/X + Q10.
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of CI + III activity (Fig. 2D) and the normalization of CII + III activity
(Fig. 2E). On the contrary, vehicle or ubiquinone-10 treatments did not
change the CoQ-dependent respiratory chain activities (Fig. 2D and E).
The increase of the CoQ-dependentmitochondrial respiratory chain activ-
ities after ubiquinol-10 treatment was not due to an increase in the
supercomplex I/III formation because the ratio supercomplex I/III/free
complex III remained low in Coq9X/X mice after vehicle, ubiquinone-10
or ubiquinol-10 treatment compared to Coq9+/+ mice (Fig. 3A, B and
C). The ratio supercomplex I/III/free complex I (Fig. S3A), as well as com-
plex I in gel activity, was similar in Coq9+/+ mice and Coq9X/X mice
(Fig. S3B), while the treatments did not produce any changes on these
variables (Fig. S3).
3.4. Histopathological evaluation and oxidative damage in brain of Coq9X/X
after 2 months of treatment
Coq9X/X mice show white matter vacuolization, severe reactive
astrogliosis, reduction in neuronal dendrites and increased DNAoxidation, which were especially evident in diencephalon and
brainstem [9]. The treatment with vehicle did not produce any change
in these histopathological biomarkers because Coq9X/X animals similarly
showed white matter vacuolization (Fig. 4C and D) and proliferation of
astrocytes (Fig. 4K and L) in diencephalon, as well as increased DNA ox-
idation in diencephalon and septum–striatum (Fig. 5C, D, K and L) com-
pared to Coq9+/+ mice (Fig. 4A, B, I and J; Fig. 5A, B, I and J). Treatment
with ubiquinone-10 did not reduce the vacuolization (Fig. 4E and F) and
astrogliosis (Fig. 4M and N) in diencephalon of Coq9X/X mice, while the
immunoreactivity against 8-OHdG was slightly decreased in both dien-
cephalon (Fig. 5E and F) and septum–striatum (Fig. 5M and N). On the
contrary, treatment with ubiquinol-10 was able to reduce the
vacuolization (Fig. 4G and H) and astrogliosis (Fig. 4O and P) in
diencephalon, as well as the DNA oxidation in both diencephalon
(Fig. 5G and H) and septum–striatum (Fig. 5O and P). In brainstem,
however, both ubiquinone-10 and ubiquinol-10 treatments were able
to reduce the astrogliosis and DNA oxidation, as well as increase neuro-
nal immunoreactivity (Figs. S4 and S5). Nevertheless, the vacuolization
still persisted with both treatments (Figs. S4 and S5). The histology
Fig. 3. The experimental treatments did not correct the decrease of SC/free CIII observed in cerebral mitochondria of Coq9X/X mice. Blue-native gel electrophoresis (BNGE) followed by
immunoblotting analysis of mitochondrial supercomplexes from 3 months old (A) Coq9+/+ (N = 7) and Coq9X/X (N = 7) mice; and (B) Coq9X/X + V (N = 7), Coq9X/X + Q10 (N = 7)
and Coq9X/X + Q10H2 (N = 7). Antibody against ubiquinol-cytochrome c reductase core protein I was used to detect complex III. Antibody against Vdac1 was used as
mitochondrial loading control. (C) Densitometry analysis of supercomplexes (SC) and free complex III, expressed as the SC/free CI ratio and considering the value of Coq9+/+ as 100%.
Data are expressed as mean ± SD. V = vehicle; Q10 = ubiquinone-10; Q10H2 = ubiquinol-10. *P b 0.05; **P b 0.01 versus Coq9+/+.
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groups (Fig. S6).
3.5. Consequences of the treatments in the animal weight
Coq9X/Xmice show a reduction in the bodyweight between the age of
1 and 5 months [9]. Oral supplementationwith vehicle or ubiquinone-10
did not produce any signiﬁcant effect in body weight. On the contrary,
ubiquinol-10 treatment signiﬁcantly increased the body weight in both
male (Fig. 6A) and female (Fig. 6B) Coq9X/X mice after two months of
treatment, compared to Coq9X/X mice treated with vehicle (Movie S1).
4. Discussion
Therapy based on oral supplementation with ubiquinone-10 has
shown contradictory results in the treatment of primary and secondary
CoQ10 deﬁciencies, mitochondrial diseases and other neurological
diseases like Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lat-
eral Sclerosis or Huntington's Disease [2–7]. These controversial results
may be due to the poor absorption and bioavailability of ubiquinone-10
[7,10,15]. In this study, we demonstrate that a water-soluble formula-
tion of ubiquinol-10, the reduced form of CoQ10, was more effective
than that of ubiquinone-10 in increasing the levels of CoQ10 in tissue
homogenates and cerebral mitochondria, resulting in an increase
of CoQ-dependent respiratory chain activities in the cerebrum of
a CoQ deﬁcient mouse model with mitochondrial encephalopathy
(Coq9X/X mice). As a consequence, ubiquinol-10 was more efﬁcient
than ubiquinone-10 in reducing the vacuolization, astrogliosis and
oxidative damage in Coq9X/X mice, thus increasing the animal body
weight.
Ubiquinone-10 in its pure form is a powder product that is insoluble
in water and has partial solubility in lipids and organic solutions, and
therefore it is poorly absorbed. The uptake of ubiquinone-10 is very
low in brain because of the blood brain barrier. Moreover, the limitation
of the exogenous ubiquinone-10 to reach mitochondria is one of the
major problems for the CoQ10 therapy because external ubiquinone-10 is distributed mainly in lysosomes and only a small amount, if any,
is found in mitochondria [10,15]. To try to increase the absorption of
ubiquinone-10, different ubiquinone-10 formulations have been
manufactured and are currently available on themarket. These formula-
tions include powder-based compressed tablets, chewable tablets,
powder-ﬁlled hard-shell capsules, softgels containing an oil suspension
and water-soluble formulations in softgel or liquid forms [8]. The latter
forms are based in the ability of dextrins to increase the solubility of
poorly water-soluble compounds with no toxic effects [16]. Our study
shows that water-soluble formulation of ubiquinone-10 in a dose of
240 mg/kg bw/day, which is equivalent to 30 mg/kg bw/day in humans
[17,18] according to the body surface area [19], is able to increase CoQ10
levels in plasma of Coq9X/X mice. The increase of plasma CoQ10 concen-
tration in Coq9X/Xmicewas reﬂected in an increase of CoQ10 levels in tis-
sues of treated mice. The lowest increase of CoQ10 in cerebrum and
cerebellum may be due to the blood brain barrier. The highest increase
of CoQ10 in the livermay be explained by itsmechanismof absorption in
the gastrointestinal system. After gastric emptying, CoQ10 is absorbed
along with other lipids as chylomicron particles in the small intestine,
and transported via lymph vessels to blood circulatory system and
then taken up by the liver cells. In the liver, CoQ10 is incorporated
with lipoproteins and released into the blood, which is used as a trans-
port vehicle to deliver CoQ10 in other tissues [20,21]. In another study,
using ubiquinone-10 in oil suspension (LiQsorb, Tishcon) in doses of
200 and 400 mg/kg bw/day for 3–4 months, the authors did not ﬁnd
any increase of CoQ10 in kidneys of a mouse model of CoQ deﬁciency
due to Pdss2mutation (Pdss2kd/kd) [22]. Similarly, the water-soluble for-
mulation of ubiquinone-10 used in our study did not show a signiﬁcant
increase in the levels of CoQ10 in kidney, suggesting that the vehicle
does not affect the absorption of ubiquinone-10 at tissue level.
Our study also shows that ubiquinol-10 has better absorption, bio-
availability and tissue uptake than ubiquinone-10 [23,24]. Importantly,
the increase of CoQ10 after ubiquinol-10 treatment is not limited to tissue
levels because CoQ10 is also increased inmitochondria from the cerebrum
of Coq9X/X mice. As a consequence, ubiquinol-10 supplementation was
able to increase the CoQ-dependent mitochondrial respiratory chain
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chondrial level. However, CI + III activity in cerebrum of Coq9X/X
mice treated with ubiquinol-10 was still half of the activity in
Coq9+/+ mice. This result may be explained by the fact that
ubiquinol-10 treatment was not able to normalize the supercomplex/
free CIII ratio (Fig. 3A) [9], and this may be justiﬁed by two possibilities:
a) the accumulation of 5-demethoxyubiquinone-9 in Coq9X/X mice,
which was not corrected by the treatments, could partially inhibit the
transfer of electrons from CI to CoQ, as it has been reported in
Caenorhabditis elegans mutant clk-1 (analog to Coq7 in human and
mouse) [25]; and b) the increase of total CoQ (CoQ9 + CoQ10) after
ubiquinol-10 treatment did not reach the required total CoQ levels in
the Q binding sites of CI and CIII. Humans and mice have two CoQ
forms, CoQ9 and CoQ10, which differ with each other in the length size
of the polyprenyl tail. While the reason to synthesize two CoQ forms is
not clear and the same functions are attributed indistinctly to the two
forms, an adequate CoQ9/CoQ10 ratio may be necessary for an optimal
performance of mitochondrial bioenergetics, including a physiological
proportion of CIII free and CIII bound to supercomplexes. In fact, each tis-
sue has a particular value on CoQ9/CoQ10 ratio, with cerebrum and cere-
bellum being the tissues with lowest CoQ9/CoQ10 ratio in mouse
(highest in human) [26]. This fact points out that CoQ9/CoQ10 ratio
seems to be tightly regulated in a tissue speciﬁcway. InCoq9X/Xmice, a de-
crease in CoQ9/CoQ10 ratio was detected in cerebrum and cerebellumhomogenates, as well as in isolated mitochondria from cerebrum
(Figs. S1 and 2C), and the ratio was even lower after ubiquinol-10 treat-
ment (Figs. S1 and2C). Future therapeutic strategies focused in increasing
the endogenous CoQ9 and CoQ10 biosynthesis could contribute to under-
stand the importance of CoQ9 in mitochondrial bioenergetics.
In addition to its bioenergetics role, CoQ10 is one of the most impor-
tant endogenous antioxidants in the cell [1]. CoQ10 deﬁciency is accom-
panied with an increased production of reactive oxygen species (ROS)
and oxidative damage to biomolecules, which leads to an increased
cell death in vitro [27,28] and in vivo [14]. Coq9X/Xmice also show an in-
crease of 8-OHdG in diencephalon, septum–striatum and brainstem, [9]
(Figs. 5 and 4s). Both ubiquinone-10 and ubiquinol-10 reduced the im-
munostaining against 8-OHdG, but the reduction was higher with
ubiquinol-10. This result may reﬂect the higher uptake of ubiquinol-
10 compared to ubiquinone-10, its higher antioxidant capacity and/or
an effect in reducing the leak of electrons through themitochondrial re-
spiratory chain.
Following the biochemical changes after the treatments, supplemen-
tationwith ubiquinol-10 reduced the vacuolization and astrogliosis in di-
encephalon, septum–striatum and, to a lesser extent, in brainstem of
Coq9X/Xmice. The lower efﬁciency of ubiquinol-10 treatment in reducing
the histopathological changes in brainstem of Coq9X/X mice compared to
diencephalon and septum–striatum may be related to an early and irre-
versible damage in this area, which is particularly susceptible in Leigh
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ubiquinone-10 in reducing the histopathological changes in Coq9X/X
mice, resulting in an increase in the bodyweight. These results are partic-
ularly important because patientswith CoQ10 deﬁciency showed variable
responses to ubiquinone-10 treatment and, in some cases, the treatment
failed or did not show a clear response [31–40], whichmay be due to the
reduced uptake of ubiquinone-10 [7]. Thus, our results suggest that
ubiquinol-10 supplementation could improve the efﬁcacy showed by
ubiquinone-10 supplementation, which will be especially important in
patientswith encephalopathy or cerebellar ataxia associated to CoQ10 de-
ﬁciency. In agreementwith that, in a patient with CoQ10 deﬁciency,men-
tal retardation, encephalomyopathy and dimorphic features due to a
COQ4 mutation, ubiquinol-10 in a dose of 15 mg/kg bw/day had the
same efﬁciency than ubiquinone-10 in a dose of 30 mg/kg bw/day [18].
5. Conclusions
Our results demonstrate that dextrin-based water-soluble formula-
tions of ubiquinol-10 have better absorption and uptake at tissue and
mitochondrial levels, which results in an increase of CoQ-dependent re-
spiratory chain activities, reduction in vacuolization, astrogliosis and ox-
idative damage in different brain areas, and an increase of body weight
in a CoQ deﬁcient mouse model with mitochondrial encephalopathy.This data suggest that water-soluble formulations of ubiquinol-10
should be preferentially used for CoQ10 therapy. However, ubiquinol-
10 supplementation did not completely rescue the encephalopathic
phenotype of the Coq9X/X mouse model. Considering that mice and
humans produce both CoQ9 and CoQ10, future therapeutic strategies fo-
cused in increasing both CoQ9 and CoQ10 levels could lead to obtain bet-
ter results.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.02.008.
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